share_log

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target

Benzinga ·  Aug 22, 2023 11:55

Cantor Fitzgerald analyst Ross Osborn reiterates Exagen (NASDAQ:XGN) with a Overweight and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment